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Abstract
Objectives—To assess paediatric antiretroviral treatment (ART) outcomes and their associations
from a collaborative cohort representing 20% of the South African national treatment programme.
Design and setting—Multi-cohort study of 7 public sector paediatric ART programmes in
Gauteng, Western Cape and KwaZulu-Natal provinces.
Subjects—ART-naïve children (≤16 years) who commenced treatment with ≥3 antiretroviral
drugs before March 2008.
Outcome measures—Time to death or loss to follow-up were assessed using the Kaplan-Meier
method. Associations between baseline characteristics and mortality were assessed with Cox
proportional hazards models stratified by site. Immune status, virological suppression and growth
were described in relation to duration of ART.
Results—The median (interquartile range) age of 6 078 children with 9 368 child-years of
follow-up was 43 (15 - 83) months, with 29% being <18 months. Most were severely ill at ART
initiation. More than 75% of children were appropriately monitored at 6-monthly intervals with
viral load suppression (<400 copies/ml) being 80% or above throughout 36 months of treatment.
Mortality and retention in care at 3 years were 7.7% (95% confidence interval 7.0 - 8.6%) and
81.4% (80.1 -82.6%), respectively. Together with young age, all markers of disease severity (low
weight-for-age z-score, high viral load, severe immune suppression, stage 3/4 disease and
anaemia) were independently associated with mortality.
Conclusions—Dramatic clinical benefit for children accessing the national ART programme is
demonstrated. Higher mortality in infants and those with advanced disease highlights the need for
early diagnosis of HIV infection and commencement of ART.
South Africa’s paediatric antiretroviral treatment (ART) programme is the largest in the
world, with an estimated 32 000 children <15 years of age on treatment at the end of 2007.1
Nevertheless the programme reaches less than half of the children estimated to need ART
according to national guidelines,2 and an even lower proportion if need is defined using
revised 2008 World Health Organization (WHO) guidelines for early treatment of HIV-
infected infants3.
Despite the size of the national programme, few individual cohorts have published treatment
outcomes, with follow-up limited to 1 year.4-6 Similar to other African countries, these
cohorts have demonstrated good short-term outcomes.7,8 However, the small size of any
individual South African cohort has limited statistical power to robustly describe
associations with mortality for all markers of disease severity9-14. Furthermore, the lack of
routinely collected national monitoring data means that South Africa has lagged behind
other southern African countries in publishing programme outcomes, and more importantly,
has no mechanism to assess the effectiveness of this enormous health service intervention.
9,15 South Africa could potentially generate valuable paediatric ART data, not only because
of the size of the programme but also due to the uniform approach to treatment shaped by
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national guidelines, as well as good access to laboratory testing facilities, particularly viral
load.
The International epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa
Collaboration includes 8 sites in South Africa providing paediatric ART at different levels of
care in 3 provinces. More than 6 000 children had commenced ART at these sites by the end
of 2007, representing >20% of children in the national programme at that time. This
collaboration therefore provides a unique opportunity to examine the effectiveness of the
South African paediatric ART programme and the extent to which national guidelines are
being followed.
Our objectives were to describe for this combined cohort the outcomes of children receiving
ART, factors associated with these outcomes, and the extent to which national programme
guidelines are being followed.
Methods
Study, design, setting and population
Data for this cohort analysis were collected prospectively at sites and transferred
anonymously to the IeDEA data centre in a standard format between May 2007 and
February 2008. Each site has institutional ethical approval for contribution of data to IeDEA
collaborative analyses.
HIV-infected, ART-naïve children with known gender and date of birth who initiated
treatment with at least 3 antiretroviral drugs at age ≤16 years on a documented date between
1 June 1999 and 29 February 2008 were included. Sites where less than 25 children met
these criteria were excluded.
Key variables
Information describing ART programmes was provided on standardised questionnaires by
site representatives. Child characteristics included measures of disease severity (WHO stage,
weight, height, haemoglobin (Hb), CD4 percentage or count, viral load) at ART initiation
and at 6-monthly follow-up intervals, together with initiating regimen. CD4 percentage and
absolute counts are reported, with the worst of these being used to determine whether the
child was severely immunosuppressed according to WHO criteria.16 Primary caregiver and
exposure to prevention of mother-to-child transmission (PMTCT) regimens were recorded.
As sites changed from the WHO 3-stage to WHO 4-stage classification of disease severity
during the latter half of 2004, all children with stage 3 or 4 disease under either system were
considered to have clinically advanced disease17. Viral loads and CD4 counts were
performed by local laboratories using standard methods. A viral load <400 copies/ml was
considered undetectable. Sex- and age-standardised z-scores for weight and height were
calculated for children ≤10 years at time of measurement using WHO 2007 growth
reference standards18.
Sites provided data on known deaths and transfers out (TFO). Children were deemed lost to
follow-up (LFU) if the last visit date was more than 6 months before date of closure of the
site database, with the last visit date used as date of LFU.
Analysis
Kaplan-Meier estimates of mortality, LFU and TFO were determined. Cox proportional
hazards models stratified by site were used to assess associations between baseline
characteristics and mortality. Multivariate models were built by sequentially adding the next
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most significant predictor variable from univariate analysis, and variables with a p-value
<0.1 after adjustment for those already in the model, or that changed the hazard ratio (HR)
for variables in the model by more than 10%, were retained. Separate models were
generated excluding the weight-for-age z-score (WAZs) as this could only be calculated for
children ≤10 years of age, and viral load, as this is not routinely available in most resource-
limited settings. Since Hb at ART initiation was only available for a third of children, this
was excluded from the main model, but a separate model was generated to assess the effect
of anaemia on mortality. Age was categorised as <12 months, 12 - 35 months and ≥36
months. WAZs were categorised as <−3, −3 to −2 and ≥−2, according to United Nations
Children’s Fund (UNICEF) definitions.19 Viral load was categorised as ≤100 000, 100 000
to 1 million and >1 million copies/ml, and year of starting ART as ≤2005 and ≥2006 as
these thresholds explained the largest amount of variability in mortality. Anaemia was
defined as Hb <8 g/dl.
As these data include a substantial proportion of children who received ART through nor-
funded programmes before commencement of National Department of Health provision on 1
April 2004, a sensitivity analysis was performed on descriptions of baseline characteristics
and survival models with data limited to those children who started ART after 31 March
2004. All statistical analyses were performed using Stata version 10 (STATA Corporation,
College Station, TX).
Results
Exclusions
Of the 8 South African IeDEA sites, 1 was excluded because the cohort comprised <25
children. The remaining data included 6 266 children on ART. Of these, 85 did not meet
inclusion criteria due to missing or inconsistent baseline data. Non-naïve patients (N=39)
and those commenced on <3 drugs (N=64) were excluded. The final data-set therefore
comprised 6 078 children (49.1% female) from 7 sites with 9 368 child-years of follow-up,
and median (interquartile range (IQR)) follow-up duration of 16 (6 - 29) months.
Contributing sites
Site characteristics are shown in Table I. Of note, sites are all urban and represent major
centres in 3 provinces (Western Cape, Gauteng and KwaZulu-Natal); however, all levels of
care are represented. There is a wide variation in the number of children being treated with
ART at different sites, from >2 000 at a site providing all levels of care in Gauteng to <300
at a smaller primary care clinic in Cape Town. The median age of children from tertiary care
sites is less than that of children from sites providing other levels of care (18.4 v. 51.9
months; p<0.0001).
Characteristics at ART start
Most children were severely ill with advanced clinical disease, immunosuppression, high
viral load and impaired growth at the start of ART (Table II). The median (IQR) age of
children commencing ART was 42.7 (14.7 - 82.5) months, with nearly 30% of children less
than 18 months of age. The starting regimen included stavudine (d4T) and lamivudine (3TC)
with either efavirenz or lopinavir/ritonavir (Kaletra) as the third drug for 81% of children.
Data were incomplete for many key variables. In particular, WHO stage was unknown for
nearly a third of children, while caregiver and PMTCT exposure information was provided
by only a few sites at which exposure status was still unknown for nearly 50%.
Characteristics at start of ART were not substantially different when the data were limited to
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those initiating treatment after formal commencement of the national programme (N=5 601,
results not shown).
Survival and retention in care
Mortality at 3 years was 7.7% (95% confidence interval (CI) 7.0 - 8.6%), and 81.4% (95%
CI 80.1 - 82.6%) of children were alive and in care at 3 years (Fig. 1, a, b). There was rapid
transfer from sites providing exclusively tertiary care to lower levels after the first 6 months
of ART, with the tertiary cohort reduced by nearly 50% at 2 years (Fig. 1, c). LFU at 1 year
increased from 2.2% (95% CI 1.1 - 4.7%) in those who commenced ART before 2004 to
8.2% (95% CI 7.1 - 9.4%) in those who commenced during or after 2006.
Mortality was higher for younger children, those with more advanced disease and those who
were more severely immunosuppressed (Fig. 1). All markers of disease severity were
independent predictors of mortality in multivariate analysis (Table III). Use of a protease
inhibitor versus a nonnucleoside reverse transcriptase inhibitor as the third drug had no
effect on mortality (p=0.572). Similarly, Hb <8 g/dl independently predicts mortality after
adjustment for disease severity, age and programme year (adjusted hazard ratio 1.65; 95%
CI 1.07 - 2.55%; p=0.024). Models excluding WAZ and viral load as predictors yielded
similar results to the full model, as did models limited to those children treated after
commencement of the national programme (results not shown).
Monitoring of viral and immune response to treatment
Follow-up measurements of CD4 and viral load are shown in Fig. 2. Notably, measurements
of CD4 and viral load at 6-monthly intervals were available for over 80% and 75% of
children respectively through to 36 months, with ≥80% of children virologically suppressed
throughout (82.4% at 3 years; 95% CI 79.4 - 85.5%). The percentage (95% CI) of children
severely immunosuppressed at 1 and 3 years dropped to 16.9% (15.4 - 18.3%) and 6.4% (4.2
- 8.6%), respectively.
Growth response to treatment
There was initial rapid weight gain from a median WAZ of −1.80 to −0.75 by 12 months,
remaining relatively constant thereafter (Fig. 3). Height increased more slowly but was still
increasing at 36 months, when a quarter of children still had a height-for-age z-score <−2.
Discussion
Main findings of the study
Outcomes of this cohort of ART-treated children in South Africa, the largest from a single
country in Africa to date, were good with mortality of 7.7% and 81.1% of children alive and
in care at 3 years. As expected, young age together with all markers of disease severity were
independent predictors of mortality. These findings are strikingly similar to those of a
similar combined cohort analysis of sub-Saharan paediatric ART programmes, the Kids’
Antiretroviral Treatment in Lower-Incomes Countries (KIDS-ART-LINC) Collaboration.8
Furthermore, follow-up monitoring of laboratory parameters was excellent, with more than
75% of children tested 6-monthly according to national guidelines. Although comparisons
with rich countries are difficult owing to the older age of ART commencement in the South
African children and inherent survival bias, the high level of virological suppression is
encouraging and compares favourably with cohorts from Europe20 and North America21 and
other African studies.7,14 Similarly, children remaining in care experienced dramatic
improvements in growth and immune status. While the proportion and absolute number of
nearly 2 000 very young children accessing ART are much greater than in most other
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African studies, across the country older children are still preferentially accessing treatment
with more than 70% of the cohort being over 18 months of age7,8,22.
Strengths and generalisablity of findings
This study is valuable because of the large number of children and length of follow-up, but
particularly because of the high absolute number of those under 18 months of age. With new
WHO guidelines encouraging early ART initiation in infants, a better understanding of
clinical outcomes in this age group is required3. In addition, the availability of regular viral
load information is unusual in the African context. Inclusion of children from a number of
different sites in 3 provinces and at different levels of care enhances representivity, while
uniformity of treatment protocols lends itself to collation into a single analysis.
Limitations
Although the study includes some of the busiest routine public sector clinics, it should be
acknowledged that IeDEA collaboration sites must have capacity for electronic collection of
routine data, which is not the norm. Some high-burden provinces are not included in the
study, and there is disproportionate representation of sites with tertiary care capacity. The
thorough monitoring and high number of infants on ART therefore probably represent best-
practice examples in well-resourced clinics.
While LFU in this study is relatively low compared with adult publications of routine cohort
data,23 there is variation in LFU at different sites. This is of concern as many of those who
are LFU are likely to have died, resulting in under-ascertainment of mortality. Indeed, while
there are various plausible explanations for the apparent protective effect on mortality of
starting ART after 2005 (including that children starting earlier are ‘sicker’ in ways not
captured by markers of disease severity available for this analysis), the contribution of
increasing LFU in later years as programmes expand should not be underestimated. In this
respect, the effect of choice of first drug (zidovudine v. stavudine) on mortality could not be
definitively assessed owing to changes in prescribing patterns after the introduction of
national treatment guidelines in 2004 and increasing LFU over time. The high transfer rate
from tertiary sites to lower levels of care limits duration of follow-up for these patients.
Systems of data collection integrated across sites are needed to ascertain outcomes for
transferred patients.
Poor integration of health information systems is also reflected in the paucity of PMTCT
exposure data. This reflects poor integration of antenatal, routine child care and HIV
services themselves within the health system, a major barrier to timeous HIV diagnosis and
referral for care of those infants infected despite PMTCT exposure7,22,24. Completeness and
accuracy of other exposure variables is also limited, while historical changes in the WHO
staging system limit its value as a measure of disease advancement.
Reflections on the South African national paediatric ART programme
This study indicates that the programme is successful for those children who access it. The
latter caveat is important, as the fact that 20% of all children are treated at a handful of sites,
all in large urban centres, suggests that considerable inequities in access are likely.
Nevertheless the fastidious monitoring, utilisation of first-line regimens recommended in
national guidelines, good survival, high proportions of children with viral suppression and
favourable immune and growth responses – at least at these sites – are encouraging. The
Western Cape has the specific aim of treating children at their nearest health centre
whenever possible, with only those warranting specialist care remaining at tertiary
facilities24. In this respect, the rapid transfer of children from exclusive tertiary to primary
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care sites, together with the difference in ages of children starting ART at different levels of
care, indicate that children are indeed receiving care at the appropriate level.
Although the cohort includes several infants, the number is negligible compared with the
estimated 64 000 new infections that occur perinatally and through breastfeeding every year.
25 Together with lack of integration of antenatal PMTCT and paediatric HIV services,
perceived and actual lack of expertise in the care of young HIV-infected infants pose
significant barriers to access for infants, who are still largely cared for at tertiary sites. These
problems need to be addressed urgently if South Africa seeks to implement revised WHO
guidelines recommending early ART for infants irrespective of disease severity3.
In this respect it should be noted that the relatively poor outcomes for infants in this study
would not necessarily be the scenario should infant ART initiation be prioritised. Disease
progression is rapid in HIV-infected infants, and in this study children commencing ART at
a young age are those whose disease progressed rapidly enough to meet previous WHO
disease severity criteria while they were still young and who were able to access treatment
before otherwise inevitable early death26. Better outcomes for older children represent a
survivor effect, with older age at ART initiation being a proxy for slower disease
progression. In contrast, other South African studies have shown excellent outcomes for
infants commencing ART before disease progression27,28.
Conclusion
This study of a substantial proportion of the South African national ART programme for
children demonstrates the dramatic clinical benefit for those accessing the programme. The
higher mortality in infants and young children and those with advanced disease highlights
the need to identify HIV-infected infants and commence ART before disease progression.
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Fig. 1.
Kaplan-Meier estimates for outcomes of (a) death, (b) death and loss to follow-up, and (c)
transfer out. Kaplan-Meier estimates of mortality by (d) age group, (e) degree of
immunosuppression and (f) WHO clinical stage.
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Fig. 2.
Immune and virological response to ART.
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Fig. 3.
Growth response to ART (only includes children with measurement at ART start and at least
one subsequent measurement).
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